Overview

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Status:
Terminated
Trial end date:
2013-03-01
Target enrollment:
0
Participant gender:
All
Summary
To assess the safety and tolerability of single subcutaneous (SC) and intravenous (IV) doses of AMG 181 in healthy subjects and of a single SC dose in subjects with mild to moderate ulcerative colitis (UC)
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Amgen
Criteria
Inclusion Criteria: Healthy Volunteers

- Healthy male or female subjects of non-reproductive potential between 18 to 45 year-of
-age

- Body Mass Index (BMI) between 18 and 34 kg/m2

- Normal physical and neurological examination, clinical laboratory values and ECG

- Additional inclusion criteria apply

Inclusion Criteria: Subjects with Mild to Moderate Ulcerative Colitis

- Male or female subjects between 18 to 55 year-of -age

- Body Mass Index (BMI) between 18 and 34 kg/m2

- Diagnosis of Ulcerative Colitis for at least 2 months

- Active, mild to moderate disease as defined by an Ulcerative Colitis Disease Activity
Index (UCDAI, aka Mayo score) score of 4 to 9 (inclusive), with a minimum
sigmoidoscopy score of 1

- Additional inclusion criteria apply

Exclusion criteria: Healthy Volunteers

- History or evidence of a clinically significant disorder (including psychiatric),
condition or disease that would pose a risk to subject safety or interfere with the
study evaluations, procedures or completion

- History of malignancy of any type, other than in situ cervical cancer or surgically
excised non-melanomatous skin cancers within the past 5 years

- Recent or on-going infection(s)

- Underlying condition(s) that predisposes the subject to infections

- Additional exclusion criteria apply

Exclusion criteria: Subjects with Mild to Moderate Ulcerative Colitis

- Disease limited to the rectum, i.e. within 20 cm of the anal verge

- Any prior gastrointestinal surgery

- Evidence of severe disease (as evidenced by an Hb concentration <11g/dL; toxic
megacolon, or an UCDAI scoreā‰„10)

- Immunosuppressive therapy with either azathioprine, methotrexate, or mercaptopurine,
within the past 3 months

- Prior exposure to a biologic agent or cyclosporine A

- Use of antibiotics within the past 2 weeks of screening and during screening period

- Use of topical (e.g. suppository or enema) mesalamine or steroids within two weeks
prior to day 1

- Additional exclusion criteria apply